125 related articles for article (PubMed ID: 35045512)
1. [A Case of Esophagogastric Junction Cancer Treated Successfully with Conversion Surgery after Complete Response to Nivolumab Treatment].
Yamazaki K; Taniguchi K; Yamane M; Hattori Y; Koizumi A; Shigehara F; Takashima J; Sugimoto H; Miura F; Matsutani N; Kobayashi H
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2121-2123. PubMed ID: 35045512
[TBL] [Abstract][Full Text] [Related]
2. [Successful Treatment of Gastric Cancer with Conversion Surgery after Nivolumab Treatment-A Case Report].
Shiraishi T; Kano M; Sakata H; Murakami K; Toyozumi T; Sekino N; Okada K; Kamata T; Ryuzaki T; Matsubara H
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1614-1616. PubMed ID: 31631152
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Long-Term Survival without Recurrence after Completion of Immunotherapy Due to Response of Third- Line Nivolumab for Liver Metastasis Recurrence of Esophagogastric Junction Cancer].
Ryuzaki T; Sentsui T; Amagai H; Sasagawa S; Kobayashi S; Tsukamoto S; Koide Y; Matsubara H
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1126-1129. PubMed ID: 38035852
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Recurrent Gastric Cancer with Durable Complete Response after Short-Term Nivolumab Therapy].
Yamamichi K; Yamada M; Sumiyama F; Yamamoto N; Hashimoto Y; Satake R; Hatta M; Sakaguchi T; Kotsuka M; Tokuhara K; Inoue K; Sekimoto M
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2052-2054. PubMed ID: 35045490
[TBL] [Abstract][Full Text] [Related]
5. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.
Matsumoto R; Arigami T; Matsushita D; Okubo K; Tanaka T; Yanagita S; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Ohtsuka T
World J Surg Oncol; 2020 Jul; 18(1):179. PubMed ID: 32693806
[TBL] [Abstract][Full Text] [Related]
6. Pathological Complete Response and Successful Conversion Surgery After Nivolumab Therapy for Stage IV Oesophagogastric Junction Cancer.
Kumamoto T; Tomita T; Hojo Y; Nakamura T; Kurahashi Y; Ishida Y; Miwa H; Hirota S; Shinohara H
In Vivo; 2021; 35(4):2247-2251. PubMed ID: 34182503
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Conversion Surgery for Unresectable Advanced Gastric Cancer of Which Metastatic Site Was Disappear by Chemotherapy but the Primary Site Was Enlarged after Five Years].
Nomura A; Akamaru Y; Nishida K; Mori S; Yasuyama A; Nomura M; Yoshikawa Y; Tamai K; Takiuchi D; Hamakawa T; Tei M; Tsujie M
Gan To Kagaku Ryoho; 2024 Apr; 51(4):473-475. PubMed ID: 38644326
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Recurrent Esophagogastric Junction Cancer Responding to Trastuzumab].
Kobayashi Y; Hirao M; Yamamoto K; Nishikawa K; Maeda S; Uemura M; Miyake M; Hama N; Miyamoto A; Miyazaki M; Ikeda M; Nakamori S; Sekimoto M; Mori K; Mano M
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2181-2183. PubMed ID: 28133262
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Long-Term Progress Control of Unresectable Progressive Gastric Cancer with Nivolumab Introduced during Effective Duration of Secondary Treatment].
Eguchi S; Akamaru Y; Wada N; Shimaoka T; Harada S; Ikeshima R; Munakata K; Takiuchi D; Hama N; Ota H; Shibata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2045-2047. PubMed ID: 35045488
[TBL] [Abstract][Full Text] [Related]
10. [Salvage Surgery for Unresectable Advanced Esophagogastric Junction Carcinoma with Multiple Liver Metastases after Successful Second-Line Treatment with Nab-Paclitaxel and Ramucirumab Following a Refractory Response to S-1 plus CDDP Therapy-A Case Report].
Fujita T; Shimizu Y; Dongping F; Yamamoto N; Kobayashi M; Iwabu H; Tsuji A
Gan To Kagaku Ryoho; 2020 Nov; 47(11):1597-1600. PubMed ID: 33268735
[TBL] [Abstract][Full Text] [Related]
11. [Long-Term Response of Nivolumab for Recurrent Lymph Nodes after Surgery for Gastric Cancer-A Case Report].
Katsuyama S; Takeno A; Masuzawa T; Sugimura K; Kihara Y; Haruna K; Shinke G; Ikeshima R; Kawai K; Hiraki M; Katsura Y; Ohmura Y; Hata T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1868-1870. PubMed ID: 35045431
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet; ; . PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
